Eighty-eight patients with acute pulmonary embolism admitted to our hospital from January 2018 to February 2020 were selected as the study subjects. According to the number table method， they were divided into control group and observation group， with 44 cases in each. The control group were given low molecular weight heparin calcium and Hua Farin combined therapy， the observation group was given low-molecular-weight heparin calcium and rivaroxaban combined therapy， and the total effective rates of treatment， coagulation function indexes， and inflammatory factor levels of the two groups were compared and analyzed.

After 6 months of treatment，the total effective rate of the observation group was 97.73% （43/44）， which was significantly higher than that of the control group 84.09% （37/44） （P < 0.05）； the prothrombin time and serum fiber of the observation group were higher than those of the control group， and the level of serum D-dimer was lower than that of the control group （P < 0.05）； the serum C-reactive protein， tumor necrosis factor alpha，and interleukin-10 levels of the observation group were lower than those of the control group （P < 0.05）.

The combination of low-molecular-weight heparin calcium and rivaroxaban in the treatment of patients with acute pulmonary embolism has a significant effect， which can not only accelerate the recovery of blood coagulation function，but also reduce inflammation.

研究对象选择河南科技大学第一附属医院2018年1月—2020年2月收治的急性肺栓塞患者88例，根据随机数字表法分为对照组与观察组，各44例，对照组给予低分子肝素钙与华法林联合治疗，观察组给予低分子肝素钙与利伐沙班联合治疗，对比分析两组的治疗总有效率、凝血功能指标、炎性因子水平。

治疗6个月后，观察组的总有效率为97.73%（43/44），高于对照组84.09%（37/44），差异有统计学意义（P < 0.05）；观察组的凝血酶原时间、血清纤维素水平均高于对照组，血清D-二聚体水平则低于对照组，差异均有统计学意义（P < 0.05）；观察组的血清C反应蛋白、肿瘤坏死因子α、白介素-10水平均低于对照组，差异有统计学意义（P < 0.05）。

低分子肝素钙与利伐沙班联合治疗急性肺栓塞患者疗效显著，不仅可以加速机体凝血功能的恢复，还可以减轻炎症反应。